A Manchester-based MedTech company developing AI-powered pathology tools has raised £425,000 in funding to help clinicians diagnose blood cancers faster and more accurately.
Spotlight Pathology, which recently featured on the GM Rising Stars of Business 2025, secured the investment in a round led by EHE Ventures.
The £425,000 is part of a larger £1.1m round expected to close in the next few months and includes a six-figure commitment from EHE Ventures via its AI Growth Fund, a multi-million-pound fund backing UK startups applying AI to solve real-world challenges, alongside support from DeepBridge Capital and Lyva Labs.
The company is building technology to support faster diagnosis of lymphoma and leukaemia.
Its platform uses proprietary computer vision models trained on UK hospital datasets to streamline lymph node and bone marrow biopsy diagnostic workflows.
With this funding, Spotlight will complete its AI platform development, secure UKCA regulatory approval, and launch pilot programs across the UK, Europe, and the US.
“Spotlight is exactly the kind of company our fund was built to support – founder-led, mission-driven, and applying AI to solve one of the most urgent challenges in global healthcare,” said Neil Vose, CEO of EHE Venture Studio.
“We’re not just providing capital. Through our Venture Studio, we’ll be working side-by-side with Sam and the team to scale the platform, accelerate development, and prepare for market entry.”
Dr. Sam Perona, CEO of Spotlight Pathology, added: “There’s a critical shortage of pathologists, and the stakes are high—delayed diagnosis means delayed treatment. Our platform gives clinicians the tools to confidently streamline diagnostic workflows.
“This investment is a major step forward in bringing our technology to market and improving outcomes for people affected by blood cancers.”